⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7259462 | 0.73 | — | — | |
| SCHEMBL276549 | 0.73 | — | — | |
| SCHEMBL8664625 | 0.73 | TSHR (0.44) | — | |
| SCHEMBL1691615 | 0.73 | — | — | |
| SCHEMBL38932 | 0.73 | — | — | |
| Zinc Ion SCHEMBL31407856 | 0.73 | CA2 (0.31) | — | |
| SCHEMBL31407802 | 0.73 | CA2 (0.36) | — | |
| Bicarbonate SCHEMBL28022644 | 0.72 | TSHR (0.41) | — | |
| SCHEMBL5252428 | 0.71 | — | — | |
| SCHEMBL1327762 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022648-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-01-28 | — | — | US | claimed |
| EP-2974728-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | Santen Pharmaceutical Co., Ltd (JP) | 2016-01-20 | — | — | EP | claimed |
| CN-105073112-A | Therapeutic agent for meibomian gland dysfunction | SANTEN PHARMACEUTICAL CO LTD | 2015-11-18 | — | — | CN | claimed |
| JP-2003511531-A | — | — | 2003-03-25 | — | — | JP | claimed |
| EP-1232196-A1 | RADIATION-CURABLE COATING COMPOSITION | DSM N.V. (NL) | 2002-08-21 | — | — | EP | claimed |
| WO-2001027181-A1 | RADIATION-CURABLE COATING COMPOSITION | DSM N.V. (NL) | 2001-04-19 | — | — | WO | claimed |
| US-11951098-B2 | Therapeutic agent for meibomian dysfunction | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-04-09 | — | — | US | disclosed |
| US-20230190716-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN DYSFUNCTION | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11612590-B2 | Therapeutic agent for meibomian dysfunction | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-28 | — | — | US | disclosed |
| US-11267797-B2 | Anticancer agent | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2022-03-08 | — | — | US | disclosed |
| CN-107823202-B | Therapeutic agent for meibomian gland dysfunction | 参天制药株式会社 | 2021-04-06 | — | — | CN | disclosed |
| US-20200317630-A1 | ANTICANCER AGENT | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-3689348-A1 | THERAPEUTIC AGENT FOR MEIBOMIAN GLAND DYSFUNCTION | Santen Pharmaceutical Co., Ltd. (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-6653330-B2 | Such as 4'-chloro-4-(5-(3-(2,4-difluorophenyl)-3-hydroxy-2-methyl-4-(1H-1,2,4 -triazol-1-y)butyl)-1,3-dioxan-2-yl)-benzanilide; antifungal activity | SANKYO COMPANY, LIMITED (JP) | 2003-11-25 | — | — | US | disclosed |
| US-20030176480-A1 | For therapy and prophylaxis of fungal infections | SANKYO COMPANY, LIMITED (JP) | 2003-09-18 | — | — | US | disclosed |
| EP-1284267-A1 | TRIAZOLE COMPOUNDS HAVING AMIDE LINKAGE | Sankyo Company, Limited (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-0420770-A1 | Process for the preparation of dihydroxy esters | EASTMAN CHEMICAL COMPANY (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4101464-A | Process for preparing foamed solids using two or more azo compounds | PENNWALT CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4029615-A | AZO COMPOUNDS | PENNWALT CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-3993609-A | ACID SENSITIVE AZO PROMOTERS | PENNWALT CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |